Prosecution Insights
Last updated: November 04, 2026
Application No. 17/275,646

METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Mar 11, 2021
Priority
Sep 19, 2018 — provisional 62/733,623 +3 more
Examiner
PETRASH, HILARY ANN
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alpine Immune Sciences Inc.
OA Round
5 (Non-Final)
65%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
42 granted / 65 resolved
+4.6% vs TC avg
Strong +51% interview lift
Without
With
+51.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
21 currently pending
Career history
97
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
24.6%
-15.4% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
33.4%
-6.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 65 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are currently pending and under consideration. Priority In view of Applicant pointing to the particular paragraphs in US Provisional Application 62/733,625 (referred to herein as ‘625) filed September 19, 2018 which provide support for the particular dose range and timing the instant claims will receive benefit of the US Provisional Application ‘625 filed 19 September 2018. Claim Interpretation Claims 1, 8 recites a method of treating cancer in a subject, the method comprising administering a variant CD80-Fc fusion protein in an amount of between 0.1 mg/kg to 1.0 mg/kg, inclusive, once a week (Q1W) or once every three weeks (Q3W) (see claim 1 lines 3-5). This claim is interpreted as requiring a minimum of two doses as the language of the claim recites “once a week” and “once every three weeks”. Therefore, administration of a single dose within the recited dose range is not within the scope of claim 1. Withdrawn Rejections In view of Applicant submitting a statement asserting Swanson2 and the instant application were each owned by Alpine Immune Sciences, Inc. thereby disqualifying Swanson2 as prior art under U.S.C. 102(b)(2)(C) the following rejections: the 35 U.S.C. 103 rejection of claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 83, 86, 90-97, and 224-227 over Demonte, Swanson2, and Kornacker2, wherein Swanson2 qualifies as prior art under 35 U.S.C. 102(a)(2), and the 35 U.S.C. 103 rejection of claims 1, 55, 56, and 59 over DeMonte, Swanson2, Kornacker2, and Horn (see Horn et al. as cited on the IDS dated 02/15/2022) as evidenced by Tirapu (as cited on PTO-892 dated 04/10/2024), wherein Swanson2 qualifies as prior art under 35 U.S.C. 102(a)(2). are hereby withdrawn. Maintained Rejections Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 2, 7, 8, 14, 15, 23, 24, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97 and 224-227 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Applicant argues amending the claim to recite “wherein the IgV domain is amino acids 35-141 of Seq ID No: 1” (see Response to Non-final received 16 July 2025, referred to herein as Remarks, pg. 11 2nd full para). Claim 1 has been amended to recite two different sequence identifiers. Previous versions of the claim recited only Seq ID No: 2 and the amino acid residues (i.e., 35-141) corresponding to the IgV domain. Thus, the variant CD80 extracellular domain or a portion thereof was derived from Seq ID No: 2. However, amending the claim to recite Seq ID No: 1 now renders the scope of the claim unclear. For example, is the “wherein the IgV domain is amino acids 35-141 of Seq ID No: 1” in lines 11-12 intended to modify the IgV domain recited in line 6 or alternatively line 11. It is also unclear how the claimed substitutions relate to Seq ID No: 1. For example, are the substitutions relative to amino acids in Seq ID No: 1, in which case the amino acids do not correspond to the positions numbers claimed (e.g., position 18 of Seq ID No: 1 is N). Alternatively, are the positions relative to the subsequence of amino acids 35-141 of Seq ID No: 1, if so, is position 35 now position 1. Examiner recommends claim 1 be amended to recite, “set forth in Seq ID No. 2 or a portion thereof comprising the IgV domain, wherein the IgV domain comprises amino acid residues 1-X of Seq ID No: 2” (lines 11-12). Therefore, the U.S.C. 112(b) rejection of claims 1, 2, 7, 8, 14, 15, 23, 24, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97 and 224-227 is hereby maintained. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 83, 86, 90-97, and 224-227 are rejected under 35 U.S.C. 103 as being unpatentable over WO2018/022945 A1 (referred to herein as Demonte, as cited on the IDS dated 02/15/2022 as #144) published 1 February 2018, WO2017/181152 A2 (referred to herein as Swanson2 for clarity over the previous Swanson reference, as cited on the IDS dated 02/15/2022 #142) published 19 October 2017, and WO2017/048878 A1 (referred to herein as Kornacker2 for clarity over the previous Kornacker reference, as cited on the IDS dated 02/15/2022 #138) published 23 March 2017. It is noted DeMonte, Swanson2, and Kornacker2 qualify as prior art under 35 U.S.C. 102(a)(1). It is noted Swanson2 is drawn to PCT/US2017/027817 which is also related to the following US Patents: 11,078,282 B2, 11,498,967 B2, 11,479,609 B2, 11,117,950 B2 and 11,359,022 B2. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Applicant has asserted Swanson2 is disqualified as prior art under 35 U.S.C. 102(b)(1)(A) because the inventors on Swanson2 are those of the present application (see Remarks pg. 12, end of 1st full para). However, Swanson2 was published before 19 September 2018 and the discloses Michael Kornacker as an inventor who is not listed as an inventor on the instant application; therefore, Swanson2 qualifies as prior art under 35 U.S.C. 102(a)(1). Applicant argues Swanson2 does not disclose the D90G substitution, Demonte and Kornacker 2 do not teach or suggest a method of treating cancer comprising the instantly claimed substitutions in the variant CD80-Fc protein, and an ordinary artisan would not deviate from the substitutions taught by Demonte and Kornacier2 (see Remarks pg. 12, 5th para-pg. 13, 2nd para). First, in response to Applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Second, the language of claim 1 recites, “the variant CD8 extracellular domain or the portion thereof comprises the amino acid substitutions” (i.e., open language); therefore, while the instantly claimed substitutions may be discloses with other substitutions the other substitutions are permissible given the open language allows for unrecited elements (see MPEP § 2111.03(I)). As set forth in the Non-Final mailed 28 March 2025, an ordinary artisan would combine H18Y/A26E/E35D/M47L/V68M/A71G/D90G given i. Demonte teaches the particular position and substitutions H18Y, A26E, E35D, M47L, V68M, and A71G and the particular position 90, ii. Kornacker2 teaches the D90G in particular, and iii. Swanson2 provides further support disclosing substitutions at one or more positions including 90. Therefore, a person of ordinary skill in the art selecting from known mutations that increase PD-L1 binding would involve choosing from a finite number of identified predictable solutions, with a reasonable expectation of success (see MPEP § 2143). Therefore the 35 U.S.C. 103 rejection of claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 83, 86, 90-97, and 224-227 over Demonte, Swanson2, and Kornacker2 is hereby maintained. Claims 1, 55, 56, and 59 are rejected under 35 U.S.C. 103 as being unpatentable over DeMonte, Swanson2, Kornacker2, and Horn (see Horn et al. as cited on the IDS dated 02/15/2022) as evidenced by Tirapu (as cited on PTO-892 dated 04/10/2024). It is noted, DeMonte, Swanson2, and Kornacker2 qualifies as 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) art. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Applicant argues Swanson2 does not qualify as prior art under 35 U.S.C. 102(a)(1) or 35 U.S.C. 102(a)(1) and Horn does not cure the deficiencies of DeMonte, Swanso2, and Kornacker (see Remarks pg. 14, 1st and 2nd para). For the reasons set forth above the 35 U.S.C. 103 rejection of claims 1, 55, 56, and 59 is hereby maintained. Claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 83, 86, 90-97, and 224-227 are rejected under 35 U.S.C. 103 as being unpatentable over WO2018/022945 A1 (referred to herein as Demonte, as cited on the IDS dated 02/15/2022 as #144) published 1 February 2018, WO2016/168771 (referred to herein as Swanson3 for clarity over the previous Swanson reference, as cited on the IDS dated 02/15/2022 #134) published 20 October 2016, and WO2017/048878 A1 (referred to herein as Kornacker2 for clarity over the previous Kornacker reference, as cited on the IDS dated 02/15/2022 #138) published 23 March 2017. It is noted DeMonte, Swanson3, and Kornacker2 qualify as 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) art. It is noted Swanson3 is drawn to PCT/US2016/027995 which is also related to US Patent 11,319,359 B2. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Applicant argues DeMonte and Kornacker2 do not teach or suggest a method of treating a cancer in a subject comprising administering a variant CD80-Fc comprising the instantly claimed substitutions, an ordinary artisan would have no reason to deviate from the substitutions taught individually by DeMonte, Swanson3, and Kornacker2, and references do not teach wherein the tumor is positive for PD-L1 or CD28 and/or surface negative for CD80 or CD86 (see Remarks pg. 15, 2nd and 3rd para). First, DeMonte discloses, “The present disclosure relates to therapeutic compositions for modulating immune response in the treatment of cancer” (see DeMonte pg. 1 para [0003]), and “the disease or condition is a tumor or cancer” (see DeMonte pg. 15 para [0044]). Kornacker2 discloses, “the present invention relates to transmembrane immunomodulatory proteins (TIPs) and immune cells engineered to express such immunomodulatory proteins for modulating immune response in the treatment of cancer” (see Kornacker2 pg. 1 para [0003]), “the provided TIP-engineered cells provide an immunotherapy platform… in the treatment of a variety of oncological and immunological indications” (see Kornacker2 pg. 11 para [0045]), and “other cancers which can be treated by the methods of the invention” (see Kornacker2 pg. 74 para [0204]). Thus, both DeMonte and Kornacker disclose methods of treating cancer. Second, in response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Demonte teaches H18Y, A26E, E35D, M47L, V68M, and A71G substitutions across various CD80 variants increase PD-L1 binding and suggests position D90 is also mutation tolerant (see DeMonte pgs. 92-94, Table 3, pg. 211, Table 13A, e.g., Seq ID Nos: 819, 859, 873, 875, 967, 981, and 989) while both Kornacker2 and Swanson3 disclose D90G also increased PD-L1 binding (see Kornacker pg. 52 Table 2; Swanson3 pgs. 50-51 Table 2). Therefore, a person of ordinary skill in the art would have modified a variant 80 polypeptide in a CD112 linked to CD80 polypeptide to comprise H18Y/A26E/E35D/M47L/V68M/A71G/D90G given DeMonte discloses the H18Y, A26E, E35D, M47L, V68M, and A71G substitutions and position D90 is mutation tolerant while Kornacker2 and Swanson3 teach the particular D90G substitution also increases PD-L1 binding. Swanson3 also teaches substitutions at up to ten positions of the wildtype CD80. Selecting from known mutations that increase PD-L1 binding would involve choosing from a finite number of identified predictable solutions, with a reasonable expectation of success (see MPEP § 2143). Third, the language of claim 1 recites, “the variant CD8 extracellular domain or the portion thereof comprises the amino acid substitutions” (i.e., open language); therefore, while the instantly claimed substitutions may be discloses with other substitutions the other substitutions are permissible given the open language allows for unrecited elements (see MPEP § 2111.03(I)). Fourth, in response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., wherein the tumor is positive for PD-L1 or CD28 and/or surface negative for CD80 or CD86) are not recited in the rejected claim(s). It is noted, the recited limitation is set forth in instant claim 55 which is not rejected here. Applicant is arguing limitations not recited in the instant claims. Therefore, the 35 U.S.C. 103 rejection of claims 1, 2, 7, 8, 14, 15, 23, 24, 32, 43-45, 47-49, 83, 86, 90-97, and 224-227 over DeMonte, Swanson3, and Kornacker2. It is noted DeMonte, Swanson3, and Kornacker2 qualify as 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) art. Claims 1, 55, 56, and 59 are rejected under 35 U.S.C. 103 as being unpatentable over DeMonte, Swanson3, Kornacker2, and Horn (see Horn et al. as cited on the IDS dated 02/15/2022) as evidenced by Tirapu (as cited on PTO-892 dated 04/10/2024). It is noted, DeMonte qualifies as 35 U.S.C. 102(a)(1) and 35 U.S.C. 102(a)(2) art. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Applicant has argued for the reasons set forth above (i.e., Horn does not cure the deficiencies of DeMonte, Swanson3, and Kornacker2) the rejection should be withdrawn; however, the 35 U.S.C. 103 rejections above are maintained. Thus, for the reasons set forth above the 35 U.S.C. 103 rejection of claims 1, 55, 56, and 59 is hereby maintained. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 12, 13, 17, 19, and 23 of U.S. Patent No. 11,639,375 B2 (referred to herein as ‘375 patent, as cited in IDS mailed 1 March 2024), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 4-9, 17, 18, 20, 27, and 28 of U.S. Patent No. 11,230,588 B2 (referred to herein as ‘588 patent, as cited in IDS mailed 15 February 2022), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 12, 17, 18, and 20 of U.S. Patent No. 11,117,948 B2 (referred to herein as ‘948 patent, as cited in IDS mailed 15 February 2022), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4, 6, 10, and 12-14 of U.S. Patent No. 11,096,988 B2 (referred to herein as ‘988 patent, as cited in IDS mailed 15 February 2022), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4, 6, 7, and 9 of U.S. Patent No. 11,117,949 B2 (referred to herein as ‘949 patent, as cited in IDS mailed 15 February 2022), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 3 of U.S. Patent No. 11,117,950 B2 (referred to herein as ‘950 patent, as cited in IDS mailed 15 February 2022), Horn, and Kornacker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 8, 12, 29, 32, 38, 69, 75, 147, and 148 of the copending Application 18/182,308 (referred to herein as ‘308 application) in view of Horn and Kornacker2 as evidenced by Tirapu. This is a provisional nonstatutory double patenting rejection. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4, 8, 10, 11, 15, 19, 20, 23, 25, 26 and 30 of U.S. Patent No. 11,078,282 B2 (referred to herein as ‘282 patent, as cited on the IDS dated 02/15/2022), Horn, DeMonte, and Kornaker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2-8, 13, 14, 16, 18, and 19 of U.S. Patent No. 11,498,967 B2 (referred to herein as ‘967 patent, as cited on the IDS dated 03/01/2024), Horn, DeMonte, and Kornaker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-7 and 10-16 of U.S. Patent No. 11,479,609 B2 (referred to herein as ‘609 patent, as cited on the IDS dated 03/01/2024), Horn, DeMonte, and Kornaker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 9-14, 17, and 19 of U.S. Patent No. 11,359,022 B2 (referred to herein as ‘022 patent, as cited on the IDS dated 03/01/2024), Horn, DeMonte, and Kornaker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 and 5-7 of U.S. Patent No. 11,319,359 B2 (referred to herein as ‘359 patent, as cited on the IDS dated 03/01/2024), Horn, DeMonte, and Kornaker2 as evidenced by Tirapu. Claims 1, 2, 7, 8, 14, 15, 32, 43-45, 47-49, 55, 56, 59, 83, 86, 90-97, and 224-227 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 126, 129, 132, 135, 136, 196, 197-201, 204, of the copending Application 17/962,413 (referred to herein as ‘413 application) in view of Horn, DeMonte, and Kornacker2 as evidenced by Tirapu. This is a provisional nonstatutory double patenting rejection. Applicant's arguments filed 16 July 2025 have been fully considered but they are not persuasive. Similar to above Applicant argues the references do not teach a variant CD80 comprising the instantly claimed substitutions (see Remarks pg. 18, 2nd and 6th full para, pg. 19, 2nd and 6th para, pg. 20, 2nd full para, para spanning pgs. 20-21) or they rejections be held in abeyance until there is allowable subject matter (see Remarks pg. 17, 5th para, pg. 20, 5th full para). Therefore, for the reasons stated above and no allowable subject matter the above listed nonstatutory double patenting rejections are hereby maintained. Conclusion No claim allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HILARY ANN PETRASH whose telephone number is (703)756-4630. The examiner can normally be reached Monday-Friday 8:30-4:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Daniel E. Kolker can be reached at 571-272-3181. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /H.A.P./Examiner, Art Unit 1644 /AMY E JUEDES/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Show 4 earlier events
Feb 13, 2025
Request for Continued Examination
Feb 14, 2025
Response after Non-Final Action
Mar 28, 2025
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Jul 16, 2025
Response Filed
Sep 24, 2025
Final Rejection mailed — §103, §112, §DOUBLEPATENT
Dec 23, 2025
Request for Continued Examination
Dec 30, 2025
Response after Non-Final Action
Nov 02, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780914
ANTI-TIGIT ANTIBODY AND METHODS OF USE THEREOF
3y 9m to grant Granted Nov 03, 2026
Patent 12760102
ANTIBODIES SPECIFIC TO CTLA-4 AND USES THEREOF
5y 6m to grant Granted Oct 13, 2026
Patent 12760123
BISPECIFIC ANTIBODIES BINDING HVEM AND CD9
4y 2m to grant Granted Oct 13, 2026
Patent 12729232
ARTIFICIAL ANTIGEN PRESENTING CELLS FOR GENETIC ENGINEERING OF IMMUNE CELLS
3y 9m to grant Granted Sep 08, 2026
Patent 12721901
ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF
4y 5m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+51.4%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 65 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month